Case Study 2 — The Regulated Comparison

Direct-to-consumer advertising for an approved drug, and what the contrast reveals

No individual, company, product, or platform is named. This case examines a rule set, not an advertiser.

Case Study 1 described a marketing layer operating with very few constraints on what it could claim. This case describes the opposite end of the same spectrum: what happens when a manufacturer of an approved medicine wants to speak directly to consumers. Reading the two side by side is the point. The contrast is where the chapter's §42.7 thesis becomes concrete — the rules attach to what an entity is legally selling, and the entity with the most evidence is the one most tightly bound.

1. An unusual permission

Begin with a fact that surprises most people outside the United States and many inside it: direct-to-consumer advertising of prescription medicines is broadly permitted in only two countries in the world — the United States and New Zealand. Most jurisdictions prohibit it outright, permitting manufacturers to promote prescription products to healthcare professionals only, with consumer-facing communication limited to disease-awareness material that does not name a product.

That asymmetry is worth holding onto, because it means everything in this case study is a policy choice, not a law of nature. The near-universal position among regulators is that consumer advertising of prescription drugs should not exist. The arguments on the other side — that it informs patients, reduces stigma, and prompts undiagnosed people to seek care — are real arguments and this case takes them seriously in §5.

2. What the rules actually require

Where consumer advertising of an approved drug is permitted, it is permitted under conditions. The following are the load-bearing ones. Chapter 38 owns the full architecture; this is the promotional slice.

Claims must be consistent with the approved labeling. The advertisement may say what the label says the drug is for, in the population the label describes. Not more. A benefit demonstrated in a trial but not reflected in the label is not available to the advertiser.

Risk information must be presented with fair balance. Benefits and risks must be conveyed with comparable prominence — not merely both present, but presented such that neither is functionally buried. Broadcast advertisements must include a major statement of the most important risks, and recent rulemaking has tightened the requirement that this statement be delivered in a clear, conspicuous, and neutral manner: audio that is audible and understandable, text that is legible, and no competing visual or musical elements engineered to make the risk section forgettable.

Adequate provision must be made for the full prescribing information. A broadcast advertisement that names both the product and its use must direct consumers to a source for the complete information. A print advertisement carries a brief summary of the labeling.

Promotion of unapproved uses is prohibited. A manufacturer may not promote its product for an indication it has not obtained, regardless of how much evidence it believes it has.

Materials are submitted to the regulator. Promotional pieces are filed at the time they are first disseminated, which creates a record and a target for enforcement.

And enforcement exists and is used. The regulator issues untitled letters and warning letters for promotional violations — most commonly for overstating efficacy, minimizing risk, making unsupported comparative claims, or omitting material information. These letters are public documents, and reading a few of them is one of the most instructive hours available to anyone learning this material.

3. What that produces, in practice

Anyone who has seen one of these advertisements knows the shape it takes: a substantial portion of the runtime devoted to a spoken list of adverse effects, delivered over pleasant imagery.

The pleasant imagery is the advertiser optimizing within the constraint, and it is worth naming honestly — fair balance governs the presence and prominence of the risk information, not the emotional valence of everything surrounding it. That is a real limitation of the rule, and it is where most substantive criticism of permitted consumer advertising lands.

But now notice what the constraint did accomplish, because it is easy to miss while being annoyed by the format:

• The advertisement names a specific product with a specific approved indication.
• The claims made are tethered to a document that a clinician can look up.
• The risks are stated out loud, in the same piece of content as the benefits, to the same audience.
• Somebody is legally accountable for every sentence, and a regulator has a filed copy.

Not one of those four properties held for the marketing described in Case Study 1.

4. The comparison, side by side

Read the last row against the first. The entity with the most evidence operates under the tightest constraint on speech; the entities with the least operate under the loosest. That is not hypocrisy and not an oversight. It is a direct consequence of the fact that promotional rules attach to approvals, and only one of these parties has one.

5. The honest case for the permission

This case study would be dishonest if it presented consumer advertising of approved drugs as simply good because it is regulated. The evidence is genuinely mixed and the literature says so.

The case for. It informs people that a treatment exists for a condition they have been enduring; it prompts consultations that would not otherwise happen; it reduces stigma for conditions people are reluctant to raise; and in under-diagnosed conditions it demonstrably increases the number of people who seek assessment. Those are real effects and they are not trivial.

The case against. It also increases requests for branded products where a cheaper or better- established option exists; it shifts prescribing toward newer drugs with shorter safety records; it can medicalize ordinary variation; and the advertising spend is concentrated on products where the commercial return is greatest rather than where the clinical need is greatest.

The unresolved part. The two effects are not separable in observational data. An increase in consultations contains both the person who genuinely needed assessment and the person who did not, and the studies that measure volume rarely measure appropriateness. This is exactly the ⚠️ structure of the telehealth access rating in §42.2, and for exactly the same reason.

6. What this contrast is good for

Three transferable conclusions.

A constrained claim is not a true claim, and an unconstrained claim is not a false one. Regulation governs what may be said, which is a different variable from whether it is so. Confusing the two produces both of this chapter's characteristic errors at once.

The most reliable signal in a piece of promotional content is what it is obligated to include. An advertisement that states risks does so because it must. An advertisement that states none may be operating under no such obligation — and the absence of a risk statement is therefore information about the regulatory position of the speaker, not about the safety of the product.

And the gap is structural, so closing it requires structural work. You cannot close it by asking creators to be more careful, because the constraint that binds the manufacturer is attached to something the creator does not have. This is why §42.7 concluded that the remedies that do reach creators — disclosure of material connections, prohibitions on deceptive claims, substantiation requirements — target the commercial relationship rather than the opinion.

Discussion questions

1. Only two countries broadly permit consumer advertising of prescription medicines. Construct the strongest argument for each position — permit and prohibit — and identify the empirical question that, if answered, would settle it. Then explain why that question is hard to answer.

2. Fair balance governs the presence and prominence of risk information but not the emotional tone of the surrounding content. Design a rule that would address the surrounding content, then identify what your rule would break or be unable to define.

3. Take the four properties listed at the end of §3 and rank them by how much protection each provides an ordinary viewer. Defend your ranking, and say which one you would keep if you could keep only one.

4. §4's table shows the entity with the most evidence operating under the tightest speech constraint. Is this outcome defensible as policy? Argue both sides, and state what you think the alternative regime would actually produce.

5. §6 claims that the absence of a risk statement tells you about the regulatory position of the speaker rather than the safety of the product. Apply this to three pieces of health content you have seen recently, and note where the inference held and where it misled you.

6. Case Study 1 and Case Study 2 describe two ends of the same spectrum. Write the paragraph that would go in a policy brief explaining why an intervention aimed at the loosely regulated end is harder to design than an intervention aimed at the tightly regulated end — and what it would have to avoid breaking.